Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clomipramine in obsessive-compulsive disorder.

R J Katz1, J DeVeaugh-Geiss, P Landau

  • 1New Drug Development Department-CNS Section, CIBA-GEIGY Corporation, Summit, NJ 07901.

Biological Psychiatry
|September 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The genesis of adiabatic shear bands.

Scientific reports·2016
Same author

Brain stimulation reward: Evidence for an adrenergic contribution in the rat.

Neuroscience letters·2009
Same author

Enhancement of drug-induced motor activity by an inhibitor of phenylethanolamine-N-methyltransferase.

Neuroscience letters·2009
Same author

Dynamic recrystallization as a potential cause for adiabatic shear failure.

Physical review letters·2008
Same author

Post-mortem three-dimensional reconstruction of the entire coronary arterial circulation using electron-beam computed tomography.

Circulation·2001
Same author

Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder.

Journal of the American Academy of Child and Adolescent Psychiatry·2001

Clomipramine hydrochloride (CMI) significantly reduced obsessive-compulsive disorder (OCD) symptoms in a 10-week trial and a 1-year extension. Most CMI patients achieved subclinical OCD levels, unlike placebo responders.

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Pharmacology

Background:

  • Obsessive-compulsive disorder (OCD) is a debilitating mental health condition.
  • Previous research suggested clomipramine hydrochloride (CMI) may be effective for OCD.

Purpose of the Study:

  • To assess the efficacy and tolerability of CMI compared to placebo for OCD.
  • To evaluate long-term treatment effects in a 1-year extension study.

Main Methods:

  • A 10-week, double-blind, multicenter trial comparing CMI to placebo.
  • A 1-year double-blind extension study.
  • Utilized the NIMH global O-C scale and physician's global therapeutic effect ratings.

Main Results:

  • CMI demonstrated statistically significant reductions in OCD severity compared to placebo.

Related Experiment Videos

  • Over 50% of CMI-treated patients achieved subclinical symptom levels.
  • CMI was generally well-tolerated, with similar tolerability to placebo.

    • Conclusions:

    • Clomipramine hydrochloride is an effective treatment for OCD.
    • Sustained efficacy was observed in the 1-year extension study.
    • CMI offers a significant therapeutic benefit for individuals with OCD.